Dermapharm Holding SE

Dermapharm Holding SE

DMPHF

$47.69

Updated: 24/09/2026, 19:43:24

Market Cap
$2.36B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
DE
Stock valuation chart
One-year closing share-price history for DMPHF
Company Profile

Dermapharm Holding SE is an international pharmaceutical company specializing in off-patent branded medications, serving both domestic and global markets. Its business is structured across three distinct segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Imports, and Herbal Extracts. The company's comprehensive activities encompass the development, production, licensing, marketing, and distribution of its offerings. Its product range includes reputable generic drugs, non-prescription remedies, natural over-the-counter treatments, and a variety of other health products. These target diverse medical fields, such as vitamin and mineral supplementation, nutritional support, skin conditions (dermatology), allergies, pain relief, cardiovascular health, women's health (gynecology), and urological issues. Key brands in its portfolio feature Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, Dermapharm provides medical devices like bite away and Herpotherm, alongside specific treatments such as the Momekort nasal spray for allergy symptoms and Azedil, available as a nasal spray or eye drops. Within its Parallel Imports division, Dermapharm brings original pharmaceuticals to market under the axicorp brand. The Herbal Extracts segment supplies natural active ingredients and botanical extracts primarily for phytopharmaceuticals, nutraceuticals, and cosmetic applications. The company's distribution network reaches pharmaceutical wholesalers, individual pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

USD
OTC
CEO: Hans-Georg Feldmeier
Employees: 3,500
https://www.dermapharm.de
Asset Summaries
Latest generated summaries for DMPHF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for DMPHF.
Share price
$47.69
Market cap
$2.36B
Exchange
OTC
Currency
USD
CEO
Hans-Georg Feldmeier
Employees
3,500
IPO date
29/11/2022
Beta
0.854
Last dividend
$0.00
Day range
$47.69 – $47.69
52-week range
$39.56 – $53.00
1-day performance
0.00%
1-year performance
20.55%
Current drawdown (1Y)
-10.02%
CIK
N/A
CUSIP
N/A
ISIN
DE000A2GS5D8
Created
07/12/2025, 03:37:21
Last update
24/09/2026, 19:43:24

Track Dermapharm Holding SE with an AI analyst

See which prediction-market events move DMPHF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to DMPHF from your Railway `news_articles` table.

No news found for this symbol.